Pittsburgh, Pa.-based Cohera Medical has secured $50 million in financing led by global investment firm KKR.
The funding will support Cohera, a developer of absorbable surgical adhesives and sealants, in its efforts to market its FDA-approved TissuGlu Surgical Adhesive in the U.S.
Additionally, the financing will help the company advance clinical trials for Sylys, a surgical sealant under development for bowel repair. Sylys, which received CE Mark last year, has been designated as an expedited access pathway device by the FDA because of its potential to address gastrointestinal leakage.
KKR’s health care investing team director Ali Satvat will join the Cohera’s board of directors as part of the transaction. — Michael Cipriano